82 related articles for article (PubMed ID: 20599864)
1. Effect of preanalytical variables on myeloperoxidase levels.
Wendland AE; Camargo JL; Polanczyk CA
Clin Chim Acta; 2010 Nov; 411(21-22):1650-5. PubMed ID: 20599864
[TBL] [Abstract][Full Text] [Related]
2. Myeloperoxidase concentrations in EDTA-plasma of healthy subjects are discordant with concentrations in heparin-plasma and serum.
Scheffer PG; van der Zwan LP; Schindhelm RK; Vermue HP; Teerlink T
Clin Biochem; 2009 Sep; 42(13-14):1490-2. PubMed ID: 19524564
[TBL] [Abstract][Full Text] [Related]
3. Effects of preanalytical variables on peptide and protein measurements in human serum and plasma: implications for clinical proteomics.
Rai AJ; Vitzthum F
Expert Rev Proteomics; 2006 Aug; 3(4):409-26. PubMed ID: 16901200
[TBL] [Abstract][Full Text] [Related]
4. Development of an ELISA for myeloperoxidase on microplate: normal reference values and effect of temperature on specimen preparation.
Chang PY; Wu TL; Hung CC; Tsao KC; Sun CF; Wu LL; Wu JT
Clin Chim Acta; 2006 Nov; 373(1-2):158-63. PubMed ID: 16815352
[TBL] [Abstract][Full Text] [Related]
5. Determination of myeloperoxidase in EDTA plasma: comparison of an enzyme-linked immunosorbent assay with a chemiluminescent automated immunoassay.
Zelzer S; Khoschsorur G; Stettin M; Weihrauch G; Truschnig-Wilders M
Clin Chim Acta; 2009 Aug; 406(1-2):62-5. PubMed ID: 19463803
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of plasma myeloperoxidase in ESRD patients.
Wang AY; Lam CW; Chan IH; Wang M; Lui SF; Sanderson JE
Am J Kidney Dis; 2010 Nov; 56(5):937-46. PubMed ID: 20638167
[TBL] [Abstract][Full Text] [Related]
7. Effect of blood sample handling post-collection on Erysipelothrix rhusiopathiae antibody titres.
Neumann EJ; Bonistalli KN
Vet J; 2009 Jun; 180(3):325-9. PubMed ID: 18783968
[TBL] [Abstract][Full Text] [Related]
8. Limited preanalytical requirements for insulin measurement.
Vogeser M; Parhofer KG
Clin Biochem; 2005 Jun; 38(6):572-5. PubMed ID: 15885238
[TBL] [Abstract][Full Text] [Related]
9. Effect of time, temperature and anticoagulants on in vitro complement activation: consequences for collection and preservation of samples to be examined for complement activation.
Mollnes TE; Garred P; Bergseth G
Clin Exp Immunol; 1988 Sep; 73(3):484-8. PubMed ID: 2463123
[TBL] [Abstract][Full Text] [Related]
10. Preanalytical influences on the measurement of visfatin by enzyme immuno assay.
Nüsken KD; Nüsken E; Petrasch M; Rauh M; Dötsch J
Clin Chim Acta; 2007 Jul; 382(1-2):154-6. PubMed ID: 17499682
[No Abstract] [Full Text] [Related]
11. Effect of collection tube type and preanalytical handling on myeloperoxidase concentrations.
Shih J; Datwyler SA; Hsu SC; Matias MS; Pacenti DP; Lueders C; Mueller C; Danne O; Möckel M
Clin Chem; 2008 Jun; 54(6):1076-9. PubMed ID: 18509013
[TBL] [Abstract][Full Text] [Related]
12. Serum myeloperoxidase concentration in a healthy population: biological variations, familial resemblance and new genetic polymorphisms.
Hoy A; Trégouët D; Leininger-Muller B; Poirier O; Maurice M; Sass C; Siest G; Tiret L; Visvikis S
Eur J Hum Genet; 2001 Oct; 9(10):780-6. PubMed ID: 11781690
[TBL] [Abstract][Full Text] [Related]
13. Specimen processing time and measurement of total insulin-like growth factor-I (IGF-I), free IGF-I, and IGF binding protein-3 (IGFBP-3).
Harris TG; Strickler HD; Yu H; Pollak MN; Monrad ES; Travin MI; Xue X; Rohan TE; Kaplan RC
Growth Horm IGF Res; 2006 Apr; 16(2):86-92. PubMed ID: 16530441
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of admission myeloperoxidase levels in patients with ST-segment elevation myocardial infarction and cardiogenic shock.
Dominguez-Rodriguez A; Samimi-Fard S; Abreu-Gonzalez P; Garcia-Gonzalez MJ; Kaski JC
Am J Cardiol; 2008 Jun; 101(11):1537-40. PubMed ID: 18489929
[TBL] [Abstract][Full Text] [Related]
15. The effect of preanalytical factors on stability of the proteome and selected metabolites in cerebrospinal fluid (CSF).
Rosenling T; Slim CL; Christin C; Coulier L; Shi S; Stoop MP; Bosman J; Suits F; Horvatovich PL; Stockhofe-Zurwieden N; Vreeken R; Hankemeier T; van Gool AJ; Luider TM; Bischoff R
J Proteome Res; 2009 Dec; 8(12):5511-22. PubMed ID: 19845411
[TBL] [Abstract][Full Text] [Related]
16. Preanalytical pitfalls of blood sampling to measure true circulating matrix metalloproteinase 9 and tissue inhibitors of matrix metalloproteinases.
Jung K; Gerlach RF; Tanus-Santos JE
Clin Chim Acta; 2006 Nov; 373(1-2):180-1; author reply 182. PubMed ID: 16616058
[No Abstract] [Full Text] [Related]
17. Role of myeloperoxidase as predictor of systemic inflammatory response syndrome in patients with ST-segment elevation myocardial infarction after primary percutaneous coronary intervention.
Samimi-Fard S; Dominguez-Rodriguez A; Abreu-Gonzalez P; Enjuanes-Grau C; Blanco-Palacios G; Hernandez-Baldomero IF; Bosa-Ojeda F; Marrero-Rodríguez F
Am J Cardiol; 2009 Sep; 104(5):634-7. PubMed ID: 19699336
[TBL] [Abstract][Full Text] [Related]
18. A new easy method for specific measurement of active myeloperoxidase in human biological fluids and tissue extracts.
Franck T; Kohnen S; Boudjeltia KZ; Van Antwerpen P; Bosseloir A; Niesten A; Gach O; Nys M; Deby-Dupont G; Serteyn D
Talanta; 2009 Dec; 80(2):723-9. PubMed ID: 19836543
[TBL] [Abstract][Full Text] [Related]
19. Stability and reproducibility of simultaneously detected plasma and serum cytokine levels in asymptomatic subjects.
Hosnijeh FS; Krop EJ; Portengen L; Rabkin CS; Linseisen J; Vineis P; Vermeulen R
Biomarkers; 2010 Mar; 15(2):140-8. PubMed ID: 19848603
[TBL] [Abstract][Full Text] [Related]
20. Effect of collection tube type and freeze-thaw cycles on myeloperoxidase concentrations in blood samples of acute coronary syndrome patients.
Naz S; Ghafoor F; Iqbal IA
Ann Clin Biochem; 2017 May; 54(3):348-354. PubMed ID: 27422133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
